Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies - PubMed (original) (raw)
Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies
Lisandro D Colantonio et al. Circulation. 2016.
Abstract
Background: The use of statins increased among US adults with high coronary heart disease (CHD) risk after publication of the 2001 cholesterol treatment guidelines.
Methods and results: We analyzed the association between lipids and CHD among 9578 REasons for Geographic And Racial Differences in Stroke (REGARDS) study participants and 346,595 Kaiser Permanente Southern California (KPSC) members with baseline lipid measurements in 2003 to 2007. We performed the same analyses among 14,590 Atherosclerosis Risk In Communities (ARIC) study participants with lipid measurements in 1987 to 1989. Analyses were restricted to blacks and whites 45 to 64 years of age without CHD who were not taking statins at baseline. Total cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured at baseline. Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and ratios of total to high-density lipoprotein cholesterol and triglycerides to high-density lipoprotein cholesterol were calculated. The prevalence of diabetes mellitus, history of stroke, and antihypertensive medication use increased at higher low-density lipoprotein cholesterol in ARIC but not in REGARDS or KPSC. Over 8.9 years of follow-up, 225 CHD events occurred in REGARDS, 6547 events in KPSC, and 583 events in ARIC. After multivariable adjustment, less favorable lipid levels were associated with higher hazard ratios for CHD in ARIC. These associations were attenuated in REGARDS and KPSC. For example, the hazard ratio associated with the highest versus lowest quartile of low-density lipoprotein cholesterol (≥ 146 versus ≤ 102 mg/dL) was 1.89 (95% confidence interval, 1.42-2.51) in ARIC, 1.25 (95% confidence interval, 0.81-1.92) in REGARDS, and 1.49 (95% confidence interval, 1.38-1.61) in KPSC.
Conclusion: The association between lipids and CHD in contemporary studies may be attenuated by the preferential use of statins by high-risk individuals.
Keywords: coronary disease; epidemiology; follow-up studies; lipids.
© 2015 American Heart Association, Inc.
Figures
Figure 1
Flowchart of individuals from REGARDS, KPSC and ARIC included in the analysis. ARIC: Atherosclerosis Risk In Communities; CHD: coronary heart disease; KPSC: Kaiser Permanente Southern California; LDL-C: low-density lipoprotein cholesterol; REGARDS: REasons for Geographic And Racial Differences in Stroke; TG: triglycerides.
Figure 2
Forest-plot of hazard ratios for coronary heart disease by lipid categories in REGARDS, KPSC and ARIC. * 6,163 events from 336,851 members for the analysis of LDL-C. All analyses include adjustment by age, race, sex, education and income levels, alcohol consumption, current smoking, diabetes, reduced eGFR, stroke and use of antihypertensive medications. Analyses from REGARDS also include adjustments for region of residence. CHD definition from REGARDS and ARIC includes definite or probable MI or CHD death. CHD definition for KPSC includes non-fatal MI (defined by an inpatient stay with a discharge ICD-9 diagnosis code of 410.× in any position) or CHD death (defined by an underlying cause of death ICD-10 code I20–I25). Analyses in KPSC and ARIC are limited to 8.9 years of follow-up. Categories of serum lipids were defined based on quartiles from REGARDS study participants. ARIC: Atherosclerosis Risk In Communities; CHD: coronary heart disease; eGFR: estimated glomerular filtration rate; HDL-C: high-density lipoprotein cholesterol; KPSC: Kaiser Permanente Southern California; LDL-C: low-density lipoprotein cholesterol; MI: myocardial infarction; REGARDS: REasons for Geographic And Racial Differences in Stroke; TG: triglycerides.
Comment in
- Changing Cholesterol Levels and Coronary Heart Disease Risk.
Wilson PW. Wilson PW. Circulation. 2016 Jan 19;133(3):239-41. doi: 10.1161/CIRCULATIONAHA.115.020380. Epub 2015 Dec 9. Circulation. 2016. PMID: 26659947 No abstract available.
Similar articles
- Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.
Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W; Atherosclerosis Risk in Communities Study Group. Sharrett AR, et al. Circulation. 2001 Sep 4;104(10):1108-13. doi: 10.1161/hc3501.095214. Circulation. 2001. PMID: 11535564 - Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies.
Joshi PH, Khokhar AA, Massaro JM, Lirette ST, Griswold ME, Martin SS, Blaha MJ, Kulkarni KR, Correa A, D'Agostino RB Sr, Jones SR, Toth PP; Lipoprotein Investigators Collaborative (LIC) Study Group. Joshi PH, et al. J Am Heart Assoc. 2016 Apr 29;5(5):e002765. doi: 10.1161/JAHA.115.002765. J Am Heart Assoc. 2016. PMID: 27130348 Free PMC article. - Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women.
Arsenault BJ, Rana JS, Stroes ES, Després JP, Shah PK, Kastelein JJ, Wareham NJ, Boekholdt SM, Khaw KT. Arsenault BJ, et al. J Am Coll Cardiol. 2009 Dec 29;55(1):35-41. doi: 10.1016/j.jacc.2009.07.057. J Am Coll Cardiol. 2009. PMID: 20117361 - Lipids, lipoproteins and apolipoproteins among turks, and impact on coronary heart disease.
Onat A. Onat A. Anadolu Kardiyol Derg. 2004 Sep;4(3):236-45. Anadolu Kardiyol Derg. 2004. PMID: 15355827 Review. - Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD. Rosenblit PD. Curr Diab Rep. 2019 Nov 21;19(12):146. doi: 10.1007/s11892-019-1246-y. Curr Diab Rep. 2019. PMID: 31754844 Review.
Cited by
- Blood lipid levels mediating the effects of sex hormone-binding globulin on coronary heart disease: Mendelian randomization and mediation analysis.
Yang J, Zhou J, Liu H, Hao J, Hu S, Zhang P, Wu H, Gao Y, Tang W. Yang J, et al. Sci Rep. 2024 May 25;14(1):11993. doi: 10.1038/s41598-024-62695-8. Sci Rep. 2024. PMID: 38796576 Free PMC article. - Lipoprotein subclasses are associated with Hepatic steatosis: insights from the prospective multicenter imaging study for the evaluation of chest pain (PROMISE) clinical trial.
Karady J, McGarrah RW, Nguyen M, Giamberardino SN, Meyersohn N, Lu MT, Staziaki PV, Puchner SB, Bittner DO, Foldyna B, Mayrhofer T, Connelly MA, Tchernof A, White PJ, Nasir K, Corey K, Voora D, Pagidipati N, Ginsburg GS, Kraus WE, Hoffmann U, Douglas PS, Shah SH, Ferencik M. Karady J, et al. Am J Prev Cardiol. 2024 May 5;18:100680. doi: 10.1016/j.ajpc.2024.100680. eCollection 2024 Jun. Am J Prev Cardiol. 2024. PMID: 38764778 Free PMC article. - 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders.
Solnica B, Sygitowicz G, Sitkiewicz D, Jóźwiak J, Kasperczyk S, Broncel M, Wolska A, Odrowąż-Sypniewska G, Banach M. Solnica B, et al. Arch Med Sci. 2024 Mar 18;20(2):357-374. doi: 10.5114/aoms/186191. eCollection 2024. Arch Med Sci. 2024. PMID: 38757022 Free PMC article. - Comparison between multiple logistic regression and machine learning methods in prediction of abnormal thallium scans in type 2 diabetes.
Yang CC, Peng CH, Huang LY, Chen FY, Kuo CH, Wu CZ, Hsia TL, Lin CY. Yang CC, et al. World J Clin Cases. 2023 Nov 26;11(33):7951-7964. doi: 10.12998/wjcc.v11.i33.7951. World J Clin Cases. 2023. PMID: 38075576 Free PMC article. - Distinct effects of cholesterol profile components on amyloid and vascular burdens.
Kang SH, Yoo H, Cheon BK, Park YH, Kim SJ, Ham H, Jang H, Kim HJ, Oh K, Koh SB, Na DL, Kim JP, Seo SW. Kang SH, et al. Alzheimers Res Ther. 2023 Nov 10;15(1):197. doi: 10.1186/s13195-023-01342-2. Alzheimers Res Ther. 2023. PMID: 37950256 Free PMC article.
References
- Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. - PubMed
- Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42:1208–1215. - PubMed
- Muntner P, Levitan EB, Brown TM, Sharma P, Zhao H, Bittner V, Glasser S, Kilgore M, Yun H, Woolley JM, Farkouh ME, Rosenson RS. Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999–2000 through 2009–2010. Am J Cardiol. 2013;112:664–670. - PMC - PubMed
- D'Agostino RB, Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180–187. - PubMed
- D'Agostino RB, Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–753. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01-HL080477/HL/NHLBI NIH HHS/United States
- K24 HL111154/HL/NHLBI NIH HHS/United States
- K24-HL111154/HL/NHLBI NIH HHS/United States
- U01 NS041588/NS/NINDS NIH HHS/United States
- R01 HL080477/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical